IL-17 매개 염증질환의 치료를 위한 조합 제제 및 이를 이용한 치료 방법
    23.
    发明授权
    IL-17 매개 염증질환의 치료를 위한 조합 제제 및 이를 이용한 치료 방법 有权
    用于治疗IL-17介导的炎性疾病的组合制剂及使用其的治疗方法

    公开(公告)号:KR101704815B1

    公开(公告)日:2017-02-09

    申请号:KR1020100071240

    申请日:2010-07-23

    Abstract: 본발명은아데노신생성촉진제, IL-4, IL-5, IL-9, IL-13 등의 Th2 사이토카인억제제또는이의신호전달억제제, 및요산의생성억제또는분해촉진약물을포함하는, IL-17에의해매개되는염증질환의예방용또는치료용조합제제에관한것이다. 또한본 발명은아데노신생성촉진제, Th2 사이토카인억제제또는이의신호전달억제제, 및요산의생성억제또는분해촉진약물을병합투여함으로써 IL-17에의해발생또는악화되는비호산구성또는호중구성호흡기염증질환, IL-17에의한호중구성염증을특징으로하는소화기질환, 혈관/대사질환, 피부질환, 골관절질환, 뇌신경질환, 및 IL-17에의한호중구성염증의합병증으로생기는폐암, 위암, 대장암등을예방또는치료하는방법에관한것이다.

    Abstract translation: 目的:提供通过联合给予药物有效预防或治疗IL-17介导的炎性疾病的组合制剂。 构成:用于预防或治疗IL-17介导的炎性疾病的组合制剂包含:腺苷产生启动子,Th2细胞因子抑制剂或其信号转导抑制剂,以及抑制尿酸生成或促进尿酸降解的药物。 腺苷产生促进剂是阿司匹林,其衍生物或其盐。 Th2细胞因子是IL-4,IL-5,IL-9或IL-13。

    세포의 지질막에서 유래된 나노소포체 및 이의 용도
    24.
    发明公开
    세포의 지질막에서 유래된 나노소포체 및 이의 용도 有权
    从细胞膜衍生的纳米颗粒及其用途

    公开(公告)号:KR1020160093321A

    公开(公告)日:2016-08-08

    申请号:KR1020150014164

    申请日:2015-01-29

    Abstract: 본발명은세포의지질막(cell membrane)에서유래된나노소포체(nanovesicles), 이의제조방법, 및상기나노소포체를이용한약제학적조성물, 진단키트등에관한것이다. 본발명에따른세포지질막유래나노소포체는치료용또는진단용물질전달에불필요한세포내 물질(유전물질및 세포내 단백질)이제거되어잠재적부작용을없앨수 있고, 세포또는조직타겟팅이가능하므로목표한세포또는조직에주로치료용또는진단용물질을전달하고다른곳에치료용또는진단용물질의전달을억제함으로써약물등 치료용물질의부작용을줄여서질병치료과정에서환자의고통과불편을줄일수 있으며, 치료효능을증가시킬수 있다. 또한, 질병치료용또는진단용물질이로딩된본 발명의세포지질막유래나노소포체및 그의제조방법은 in vitro 또는 in vivo에서치료또는진단용, 또는실험용으로사용될수 있다.

    Abstract translation: 本发明涉及衍生自细胞脂质膜的纳米囊,其制备方法以及使用纳米囊的药物组合物和诊断试剂盒。 根据本发明的细胞脂质膜衍生的纳米囊体不含用于递送用于治疗或诊断的材料所不需要的细胞内物质(遗传物质和细胞内蛋白质),因此不会产生潜在的副作用。 纳米泡囊能够进行细胞或组织靶向以大量递送用于靶细胞或组织的治疗或诊断的材料并且抑制用于治疗或诊断的材料到其他部位的递送,从而减少用于治疗的材料的副作用 ,例如药物,并且在治疗疾病期间减轻患者的疼痛和不便。 此外,负载有用于治疗或诊断疾病的材料的细胞脂质膜衍生的纳米囊体及其制备方法可以在体外或体内应用于治疗,诊断或实验。

    종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
    25.
    发明公开
    종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 无效
    来自肿瘤组织的纳米囊和使用相同的肿瘤疫苗

    公开(公告)号:KR1020120132183A

    公开(公告)日:2012-12-05

    申请号:KR1020110050854

    申请日:2011-05-27

    Abstract: PURPOSE: A pharmaceutical composition containing nanovesicles derived from tumor tissue and a method for treating cancer using the same are provided to enable shape changing of a nanovesicle antigen into various forms and to develop a cancer therapeutic vaccine. CONSTITUTION: A pharmaceutical composition for treating cancer contains nanovesicles derived from a tumor tissue. The tumor tissue is autologously derived from a patient with tumor or is prepared by transformation to express heat shock protein. The composition additionally contains an immunoadjuvant, polyI:C. The membrane of the nanovesicle contains cyclodextrin or polyethylene glycol. A method for preparing the nanovesicle comprises: a step of separating cells from the tumor tissue; a step of performing extrusion, sonication, cell lysis, homogenization, freezing-thawing, electroporation, mechanical lysis, or chemical treatment of a tumor cell suspension and preparing nanovesicles; a step of separating the nanovesicles from the suspension; and a step of adding the immunoadjuvant and culturing. A cancer vaccine contains a nanovesicle antigen derived from the tumor tissue.

    Abstract translation: 目的:提供含有源自肿瘤组织的纳米囊的药物组合物和使用其的治疗癌症的方法,以使纳米级抗原形状变化成各种形式并开发癌症治疗性疫苗。 构成:用于治疗癌症的药物组合物含有衍生自肿瘤组织的纳米囊。 肿瘤组织自体衍生自患有肿瘤的患者,或通过转化来表达热休克蛋白来制备。 组合物另外含有免疫佐剂,polyI:C。 纳米囊的膜含有环糊精或聚乙二醇。 制备纳米囊的方法包括:从肿瘤组织分离细胞的步骤; 进行挤出,超声处理,细胞裂解,均质化,冻融,电穿孔,机械裂解或化学处理肿瘤细胞悬浮液并制备纳米囊泡的步骤; 从悬浮液中分离纳米囊泡的步骤; 并添加免疫佐剂和培养的步骤。 癌症疫苗含有衍生自肿瘤组织的纳米级抗原。

    체액 내 세포밖 소포체의 단백질 또는 유전자 분석을 통한 염증성 질환 진단 방법
    26.
    发明公开
    체액 내 세포밖 소포체의 단백질 또는 유전자 분석을 통한 염증성 질환 진단 방법 有权
    通过分析蛋白质或体液中的细胞外基质的方法来诊断炎症疾病

    公开(公告)号:KR1020120111788A

    公开(公告)日:2012-10-11

    申请号:KR1020110029195

    申请日:2011-03-31

    Abstract: PURPOSE: A method for diagnosing inflammatory diseases and a diagnosis kit are provided to improve diagnosis accuracy. CONSTITUTION: A method for diagnosing inflammatory diseases comprises: a step of isolating cell adhesion proteins in fluid into water soluble protein fraction and extracellular endoplasmic reticulum fraction; and a step of quantitating proteins in the water soluble protein fraction and extracellular endoplasmic reticulum fraction. The proteins contain ICAM-1(intercellular adhesion molecule-1), E-selectin, and VCAM-1(vascular cell adhesion molecule-1). A method for diagnosing inflammatory diseases comprises a step of measuring the expression level of gene existing in the extracellular endoplasmic reticulum of body fluid. The cell adhesion protein is ICAM-1, E-selectin, and VCAM-1. [Reference numerals] (AA,EE) Cell culture liquid; (BB) Ultracentrifugation; (CC,FF) Soluble protein; (DD,GG) Extracellular endoplasmic reticulum

    Abstract translation: 目的:提供诊断炎性疾病的方法和诊断试剂盒,以提高诊断准确性。 构成:用于诊断炎性疾病的方法包括:将流体中的细胞粘附蛋白分离成水溶性蛋白质级分和细胞外质网层级的步骤; 以及定量水溶性蛋白质级分和细胞外质网层级蛋白质的步骤。 蛋白质含有ICAM-1(细胞间粘附分子-1),E-选择蛋白和VCAM-1(血管细胞粘附分子-1)。 用于诊断炎性疾病的方法包括测量存在于体液的细胞外质网中的基因的表达水平的步骤。 细胞粘附蛋白是ICAM-1,E-选择蛋白和VCAM-1。 (标号)(AA,EE)细胞培养液; (BB)超速离心; (CC,FF)可溶性蛋白; (DD,GG)细胞外质网

    섬유아세포성장인자-2 를 이용한 면역 보강제
    29.
    发明公开
    섬유아세포성장인자-2 를 이용한 면역 보강제 无效
    免疫调节剂使用纤维生长因子-2

    公开(公告)号:KR1020130141878A

    公开(公告)日:2013-12-27

    申请号:KR1020120064958

    申请日:2012-06-18

    Abstract: The present invention relates to an immunity reinforcing composition which contains recombined fibrobalst growth factor-2 (FGF2) as an active ingredient and is capable of containing antigens. The composition of the present invention can be used as a pharmaceutical composition and a vaccine composition for preventing or treating: infectious diseases caused by virus, bacteria, fungi, or protozoa; or inflammation diseases caused by extracellular endoplasmic reticulum secreted from the bacteria, fungi, or protozoa.

    Abstract translation: 本发明涉及含有重组的纤维素生长因子-2(FGF2)作为活性成分并能够含有抗原的免疫增强组合物。 本发明的组合物可以用作药物组合物和用于预防或治疗由病毒,细菌,真菌或原生动物引起的感染性疾病的疫苗组合物; 或由细菌,真菌或原生动物分泌的细胞外质网引起的炎症疾病。

    배아줄기세포 유래의 인공 마이크로베시클을 이용한 역분화 유도만능줄기세포의 제조방법
    30.
    发明公开
    배아줄기세포 유래의 인공 마이크로베시클을 이용한 역분화 유도만능줄기세포의 제조방법 有权
    使用衍生自胚胎干细胞的微泡制备诱导性多能干细胞的方法

    公开(公告)号:KR1020120123624A

    公开(公告)日:2012-11-09

    申请号:KR1020110040202

    申请日:2011-04-28

    CPC classification number: C12N5/0696 A61K35/545 C12N2502/02 C12N2506/13

    Abstract: PURPOSE: A method for preparing induced pluripotent stem cells by treating a composition containing a microvesicle is provided to develop cell therapeutic agent. CONSTITUTION: A method for preparing induced pluripotent stem cells comprises a step of treating somatic cells with a composition containing embryonic stem cell-derived microvesicle. The embryonic stem cells are derived from human or non-human primates, mouse, rat, dog, cat, house, or horse. The microvesicle additionally contains components except for a cell membrane of embryonic stem cells. The components are cyclodextrin or polyethylene glycol. The composition additionally contains a component except for the microvesicle, such as BFA(brefeldin A), BIX(BiP inducer X), or VPA(valproic acid). A cell therapeutic agent contains the induced pluripotent stem cells. [Reference numerals] (AA) Embryonic stem cell; (BB) Microvesicle

    Abstract translation: 目的:提供一种通过处理含有微泡的组合物制备诱导性多能干细胞的方法,以开发细胞治疗剂。 构成:用于制备诱导性多能干细胞的方法包括用含有胚胎干细胞衍生的微泡的组合物处理体细胞的步骤。 胚胎干细胞衍生自人或非人灵长类动物,小鼠,大鼠,狗,猫,家或马。 微泡除了胚胎干细胞的细胞膜外,还含有成分。 组分是环糊精或聚乙二醇。 该组合物另外含有除了微泡之外的组分,例如BFA(布雷菲德菌素A),BIX(BiP诱导剂X)或VPA(丙戊酸))。 细胞治疗剂含有诱导的多能干细胞。 (附图标记)(AA)胚胎干细胞; (BB)微囊泡

Patent Agency Ranking